[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-11-09

AUTHORS

E. J. van Helden, S. G. Elias, S. L. Gerritse, S. C. van Es, E. Boon, M. C. Huisman, N. C. T. van Grieken, H. Dekker, G. A. M. S. van Dongen, D. J. Vugts, R. Boellaard, C. M. L. van Herpen, E. G. E. de Vries, W. J. G. Oyen, A. H. Brouwers, H. M. W. Verheul, O. S. Hoekstra, C. W. Menke-van der Houven van Oordt

ABSTRACT

PurposeOne-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal antibodies. This might be a result of variable pharmacokinetics and insufficient tumor targeting. We evaluated cetuximab tumor accumulation on [89Zr]Zr-cetuximab PET/CT as a potential predictive biomarker and determinant for an escalating dosing strategy.Patients and methodsPET/CT imaging of [89Zr]Zr-cetuximab (37 MBq/10 mg) after a therapeutic pre-dose (500 mg/m2 ≤ 2 h) cetuximab was performed at the start of treatment. Patients without visual tumor uptake underwent dose escalation and a subsequent [89Zr]Zr-cetuximab PET/CT. Treatment benefit was defined as stable disease or response on CT scan evaluation after 8 weeks.ResultsVisual tumor uptake on [89Zr]Zr-cetuximab PET/CT was observed in 66% of 35 patients. There was no relationship between PET positivity and treatment benefit (52% versus 80% for PET-negative, P = 0.16), progression-free survival (3.6 versus 5.7 months, P = 0.15), or overall survival (7.1 versus 9.4 months, P = 0.29). However, in 67% of PET-negative patients, cetuximab dose escalation (750–1250 mg/m2) was applied, potentially influencing outcome in this group. None of the second [89Zr]Zr-cetuximab PET/CT was positive. Eighty percent of patients without visual tumor uptake had treatment benefit, making [89Zr]Zr-cetuximab PET/CT unsuitable as a predictive biomarker. Tumor SUVpeak did not correlate to changes in tumor size on CT (P = 0.23), treatment benefit, nor progression-free survival. Cetuximab pharmacokinetics were not related to treatment benefit. BRAF mutations, right-sidedness, and low sEGFR were correlated with intrinsic resistance to cetuximab.ConclusionTumor uptake on [89Zr]Zr-cetuximab PET/CT failed to predict treatment benefit in patients with RAS wild-type mCRC receiving cetuximab monotherapy. BRAF mutations, right-sidedness, and low sEGFR correlated with intrinsic resistance to cetuximab. More... »

PAGES

849-859

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00259-019-04555-6

DOI

http://dx.doi.org/10.1007/s00259-019-04555-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1122411406

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31705176


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cetuximab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mutation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Positron Emission Tomography Computed Tomography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins B-raf", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins p21(ras)", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Helden", 
        "givenName": "E. J.", 
        "id": "sg:person.0624671657.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624671657.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.7692.a", 
          "name": [
            "Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Elias", 
        "givenName": "S. G.", 
        "id": "sg:person.01044433531.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044433531.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gerritse", 
        "givenName": "S. L.", 
        "id": "sg:person.0775731665.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775731665.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.4830.f", 
          "name": [
            "Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Es", 
        "givenName": "S. C.", 
        "id": "sg:person.01204115344.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204115344.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.10417.33", 
          "name": [
            "Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boon", 
        "givenName": "E.", 
        "id": "sg:person.010151641705.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010151641705.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huisman", 
        "givenName": "M. C.", 
        "id": "sg:person.01006327107.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006327107.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pathology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Pathology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Grieken", 
        "givenName": "N. C. T.", 
        "id": "sg:person.011656526207.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011656526207.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dekker", 
        "givenName": "H.", 
        "id": "sg:person.01250717536.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01250717536.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Dongen", 
        "givenName": "G. A. M. S.", 
        "id": "sg:person.0732223564.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732223564.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vugts", 
        "givenName": "D. J.", 
        "id": "sg:person.0665425270.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665425270.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boellaard", 
        "givenName": "R.", 
        "id": "sg:person.01361420011.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361420011.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.10417.33", 
          "name": [
            "Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Herpen", 
        "givenName": "C. M. L.", 
        "id": "sg:person.014562003237.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014562003237.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.4830.f", 
          "name": [
            "Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Vries", 
        "givenName": "E. G. E.", 
        "id": "sg:person.012766300443.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012766300443.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Institute of Cancer Research and The Royal Marsden Hospital, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.424926.f", 
          "name": [
            "Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands", 
            "The Institute of Cancer Research and The Royal Marsden Hospital, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Oyen", 
        "givenName": "W. J. G.", 
        "id": "sg:person.0644704274.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644704274.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.4830.f", 
          "name": [
            "Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Brouwers", 
        "givenName": "A. H.", 
        "id": "sg:person.0755073020.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755073020.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Verheul", 
        "givenName": "H. M. W.", 
        "id": "sg:person.011543041217.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011543041217.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hoekstra", 
        "givenName": "O. S.", 
        "id": "sg:person.0621551653.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0621551653.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Menke-van der Houven van Oordt", 
        "givenName": "C. W.", 
        "id": "sg:person.0704276650.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704276650.01"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/35025220", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043028620", 
          "https://doi.org/10.1038/35025220"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.2010.12", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037850597", 
          "https://doi.org/10.1038/clpt.2010.12"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-014-2961-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008918527", 
          "https://doi.org/10.1007/s00259-014-2961-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2015.173", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048637377", 
          "https://doi.org/10.1038/bjc.2015.173"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-11-09", 
    "datePublishedReg": "2019-11-09", 
    "description": "PurposeOne-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal antibodies. This might be a result of variable pharmacokinetics and insufficient tumor targeting. We evaluated cetuximab tumor accumulation on [89Zr]Zr-cetuximab PET/CT as a potential predictive biomarker and determinant for an escalating dosing strategy.Patients and methodsPET/CT imaging of [89Zr]Zr-cetuximab (37 MBq/10 mg) after a therapeutic pre-dose (500 mg/m2 \u2264 2 h) cetuximab was performed at the start of treatment. Patients without visual tumor uptake underwent dose escalation and a subsequent [89Zr]Zr-cetuximab PET/CT. Treatment benefit was defined as stable disease or response on CT scan evaluation after 8 weeks.ResultsVisual tumor uptake on [89Zr]Zr-cetuximab PET/CT was observed in 66% of 35 patients. There was no relationship between PET positivity and treatment benefit (52% versus 80% for PET-negative, P = 0.16), progression-free survival (3.6 versus 5.7 months, P = 0.15), or overall survival (7.1 versus 9.4 months, P = 0.29). However, in 67% of PET-negative patients, cetuximab dose escalation (750\u20131250 mg/m2) was applied, potentially influencing outcome in this group. None of the second [89Zr]Zr-cetuximab PET/CT was positive. Eighty percent of patients without visual tumor uptake had treatment benefit, making [89Zr]Zr-cetuximab PET/CT unsuitable as a predictive biomarker. Tumor SUVpeak did not correlate to changes in tumor size on CT (P = 0.23), treatment benefit, nor progression-free survival. Cetuximab pharmacokinetics were not related to treatment benefit. BRAF mutations, right-sidedness, and low sEGFR were correlated with intrinsic resistance to cetuximab.ConclusionTumor uptake on [89Zr]Zr-cetuximab PET/CT failed to predict treatment benefit in patients with RAS wild-type mCRC receiving cetuximab monotherapy. BRAF mutations, right-sidedness, and low sEGFR correlated with intrinsic resistance to cetuximab.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00259-019-04555-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.8569345", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1297401", 
        "issn": [
          "1619-7070", 
          "1619-7089"
        ], 
        "name": "European Journal of Nuclear Medicine and Molecular Imaging", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "47"
      }
    ], 
    "keywords": [
      "PET/CT", 
      "RAS wild-type mCRC", 
      "progression-free survival", 
      "treatment benefit", 
      "cetuximab monotherapy", 
      "dose escalation", 
      "predictive biomarkers", 
      "BRAF mutations", 
      "tumor uptake", 
      "anti-EGFR monoclonal antibodies", 
      "percent of patients", 
      "advanced colorectal cancer", 
      "potential predictive biomarkers", 
      "CT scan evaluation", 
      "start of treatment", 
      "PET-negative patients", 
      "intrinsic resistance", 
      "cetuximab pharmacokinetics", 
      "stable disease", 
      "overall survival", 
      "scan evaluation", 
      "variable pharmacokinetics", 
      "tumor size", 
      "colorectal cancer", 
      "PET positivity", 
      "dosing strategies", 
      "patients", 
      "insufficient tumor targeting", 
      "cetuximab", 
      "monoclonal antibodies", 
      "CT imaging", 
      "CT", 
      "biomarkers", 
      "monotherapy", 
      "tumor targeting", 
      "mCRC", 
      "survival", 
      "pharmacokinetics", 
      "tumor accumulation", 
      "escalation", 
      "ConclusionTumors", 
      "cancer", 
      "SUVpeak", 
      "mutations", 
      "disease", 
      "benefits", 
      "uptake", 
      "weeks", 
      "antibodies", 
      "positivity", 
      "outcomes", 
      "treatment", 
      "imaging", 
      "percent", 
      "resistance", 
      "group", 
      "targeting", 
      "response", 
      "determinants", 
      "evaluation", 
      "start", 
      "sEGFR", 
      "accumulation", 
      "changes", 
      "strategies", 
      "relationship", 
      "results", 
      "size"
    ], 
    "name": "[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer", 
    "pagination": "849-859", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1122411406"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00259-019-04555-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31705176"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00259-019-04555-6", 
      "https://app.dimensions.ai/details/publication/pub.1122411406"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_814.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00259-019-04555-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00259-019-04555-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00259-019-04555-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00259-019-04555-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00259-019-04555-6'


 

This table displays all metadata directly associated to this object as RDF triples.

318 TRIPLES      22 PREDICATES      106 URIs      94 LITERALS      15 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00259-019-04555-6 schema:about N07501d197178481d9f86b28d14d52cbb
2 N30f8407d46014de3b84c8ddd29170f61
3 N4ca7cc7e9e074b32a13290cc479ed12c
4 N5d90e18cc0dd49168ff4dad8805c7a62
5 N8664b22563b44b91a8bcbfa1e67c1f87
6 Nb2a8768217cc4ae3868cd551299e8bed
7 Nff6371ce430d4d0d81ab452d1bec4061
8 Nfffedaaac7fe48c692135d0b0f48b43e
9 anzsrc-for:11
10 anzsrc-for:1112
11 schema:author N71f24360cbfb42968d722fe6364308be
12 schema:citation sg:pub.10.1007/s00259-014-2961-x
13 sg:pub.10.1038/35025220
14 sg:pub.10.1038/bjc.2015.173
15 sg:pub.10.1038/clpt.2010.12
16 schema:datePublished 2019-11-09
17 schema:datePublishedReg 2019-11-09
18 schema:description PurposeOne-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal antibodies. This might be a result of variable pharmacokinetics and insufficient tumor targeting. We evaluated cetuximab tumor accumulation on [89Zr]Zr-cetuximab PET/CT as a potential predictive biomarker and determinant for an escalating dosing strategy.Patients and methodsPET/CT imaging of [89Zr]Zr-cetuximab (37 MBq/10 mg) after a therapeutic pre-dose (500 mg/m2 ≤ 2 h) cetuximab was performed at the start of treatment. Patients without visual tumor uptake underwent dose escalation and a subsequent [89Zr]Zr-cetuximab PET/CT. Treatment benefit was defined as stable disease or response on CT scan evaluation after 8 weeks.ResultsVisual tumor uptake on [89Zr]Zr-cetuximab PET/CT was observed in 66% of 35 patients. There was no relationship between PET positivity and treatment benefit (52% versus 80% for PET-negative, P = 0.16), progression-free survival (3.6 versus 5.7 months, P = 0.15), or overall survival (7.1 versus 9.4 months, P = 0.29). However, in 67% of PET-negative patients, cetuximab dose escalation (750–1250 mg/m2) was applied, potentially influencing outcome in this group. None of the second [89Zr]Zr-cetuximab PET/CT was positive. Eighty percent of patients without visual tumor uptake had treatment benefit, making [89Zr]Zr-cetuximab PET/CT unsuitable as a predictive biomarker. Tumor SUVpeak did not correlate to changes in tumor size on CT (P = 0.23), treatment benefit, nor progression-free survival. Cetuximab pharmacokinetics were not related to treatment benefit. BRAF mutations, right-sidedness, and low sEGFR were correlated with intrinsic resistance to cetuximab.ConclusionTumor uptake on [89Zr]Zr-cetuximab PET/CT failed to predict treatment benefit in patients with RAS wild-type mCRC receiving cetuximab monotherapy. BRAF mutations, right-sidedness, and low sEGFR correlated with intrinsic resistance to cetuximab.
19 schema:genre article
20 schema:inLanguage en
21 schema:isAccessibleForFree true
22 schema:isPartOf N11fe88e14da24c6086ad40df76fbe7bf
23 Nb637ad7bfb4448b29e0f3ed07ad78948
24 sg:journal.1297401
25 schema:keywords BRAF mutations
26 CT
27 CT imaging
28 CT scan evaluation
29 ConclusionTumors
30 PET positivity
31 PET-negative patients
32 PET/CT
33 RAS wild-type mCRC
34 SUVpeak
35 accumulation
36 advanced colorectal cancer
37 anti-EGFR monoclonal antibodies
38 antibodies
39 benefits
40 biomarkers
41 cancer
42 cetuximab
43 cetuximab monotherapy
44 cetuximab pharmacokinetics
45 changes
46 colorectal cancer
47 determinants
48 disease
49 dose escalation
50 dosing strategies
51 escalation
52 evaluation
53 group
54 imaging
55 insufficient tumor targeting
56 intrinsic resistance
57 mCRC
58 monoclonal antibodies
59 monotherapy
60 mutations
61 outcomes
62 overall survival
63 patients
64 percent
65 percent of patients
66 pharmacokinetics
67 positivity
68 potential predictive biomarkers
69 predictive biomarkers
70 progression-free survival
71 relationship
72 resistance
73 response
74 results
75 sEGFR
76 scan evaluation
77 size
78 stable disease
79 start
80 start of treatment
81 strategies
82 survival
83 targeting
84 treatment
85 treatment benefit
86 tumor accumulation
87 tumor size
88 tumor targeting
89 tumor uptake
90 uptake
91 variable pharmacokinetics
92 weeks
93 schema:name [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
94 schema:pagination 849-859
95 schema:productId N58186b60de7d460e8096100353ac043b
96 Nd18f22c0e65e4c17a46f80234dba0542
97 Ndfab4287231a4ed7897aa5882c5c15a6
98 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122411406
99 https://doi.org/10.1007/s00259-019-04555-6
100 schema:sdDatePublished 2022-05-20T07:36
101 schema:sdLicense https://scigraph.springernature.com/explorer/license/
102 schema:sdPublisher N8c881ef7a71f40d28685fa9dc1f9040e
103 schema:url https://doi.org/10.1007/s00259-019-04555-6
104 sgo:license sg:explorer/license/
105 sgo:sdDataset articles
106 rdf:type schema:ScholarlyArticle
107 N000ba3a40ef14b50bde491042b1ff965 rdf:first sg:person.012766300443.59
108 rdf:rest N9f3d5829223c42ff9dbe2ebdf80d45df
109 N04ab3418a67844f4a74c2380c85505f1 rdf:first sg:person.0755073020.01
110 rdf:rest Nae43f061782c4175abcabd7e097c05e6
111 N07501d197178481d9f86b28d14d52cbb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Humans
113 rdf:type schema:DefinedTerm
114 N11fe88e14da24c6086ad40df76fbe7bf schema:issueNumber 4
115 rdf:type schema:PublicationIssue
116 N20a2118fdbb346ba8a7ae33e746d67e4 rdf:first sg:person.01361420011.63
117 rdf:rest Nc82c2290c9744c95857441e02145e9db
118 N258f3c1ed6cd44f082be7cb04ba4da77 rdf:first sg:person.0732223564.35
119 rdf:rest N49556b5b4e094c6a8c5fe43803d00614
120 N30f8407d46014de3b84c8ddd29170f61 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Mutation
122 rdf:type schema:DefinedTerm
123 N49556b5b4e094c6a8c5fe43803d00614 rdf:first sg:person.0665425270.49
124 rdf:rest N20a2118fdbb346ba8a7ae33e746d67e4
125 N4a7af56611874cbeadf740aaf817e1c7 rdf:first sg:person.011656526207.74
126 rdf:rest Nd1d21a8d1e3448969e7115e366998e6e
127 N4ca7cc7e9e074b32a13290cc479ed12c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Cetuximab
129 rdf:type schema:DefinedTerm
130 N58186b60de7d460e8096100353ac043b schema:name pubmed_id
131 schema:value 31705176
132 rdf:type schema:PropertyValue
133 N5d90e18cc0dd49168ff4dad8805c7a62 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Proto-Oncogene Proteins p21(ras)
135 rdf:type schema:DefinedTerm
136 N71f24360cbfb42968d722fe6364308be rdf:first sg:person.0624671657.22
137 rdf:rest Nf3bfeab213664fbe932921c67127b9b1
138 N8664b22563b44b91a8bcbfa1e67c1f87 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Positron Emission Tomography Computed Tomography
140 rdf:type schema:DefinedTerm
141 N8815c846ad9047fda2fe87336f418e31 rdf:first sg:person.0775731665.95
142 rdf:rest Nb14ca9609e1c4a1db535438b87d3a137
143 N8c881ef7a71f40d28685fa9dc1f9040e schema:name Springer Nature - SN SciGraph project
144 rdf:type schema:Organization
145 N9f3d5829223c42ff9dbe2ebdf80d45df rdf:first sg:person.0644704274.30
146 rdf:rest N04ab3418a67844f4a74c2380c85505f1
147 Nae43f061782c4175abcabd7e097c05e6 rdf:first sg:person.011543041217.55
148 rdf:rest Ne2d246118c2a4f4080c19670adaa1e7f
149 Nb14ca9609e1c4a1db535438b87d3a137 rdf:first sg:person.01204115344.29
150 rdf:rest Nd064a35da19f48e7b2abf8a5553bdd6d
151 Nb2a8768217cc4ae3868cd551299e8bed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Biomarkers
153 rdf:type schema:DefinedTerm
154 Nb637ad7bfb4448b29e0f3ed07ad78948 schema:volumeNumber 47
155 rdf:type schema:PublicationVolume
156 Nc623393ec99b463a87168d4b377fcca2 rdf:first sg:person.01006327107.21
157 rdf:rest N4a7af56611874cbeadf740aaf817e1c7
158 Nc82c2290c9744c95857441e02145e9db rdf:first sg:person.014562003237.68
159 rdf:rest N000ba3a40ef14b50bde491042b1ff965
160 Nd064a35da19f48e7b2abf8a5553bdd6d rdf:first sg:person.010151641705.79
161 rdf:rest Nc623393ec99b463a87168d4b377fcca2
162 Nd18f22c0e65e4c17a46f80234dba0542 schema:name doi
163 schema:value 10.1007/s00259-019-04555-6
164 rdf:type schema:PropertyValue
165 Nd1d21a8d1e3448969e7115e366998e6e rdf:first sg:person.01250717536.24
166 rdf:rest N258f3c1ed6cd44f082be7cb04ba4da77
167 Ndfab4287231a4ed7897aa5882c5c15a6 schema:name dimensions_id
168 schema:value pub.1122411406
169 rdf:type schema:PropertyValue
170 Ne2d246118c2a4f4080c19670adaa1e7f rdf:first sg:person.0621551653.25
171 rdf:rest Nf134788acbc244aab3aaf0a6c6ad03e7
172 Nf134788acbc244aab3aaf0a6c6ad03e7 rdf:first sg:person.0704276650.01
173 rdf:rest rdf:nil
174 Nf3bfeab213664fbe932921c67127b9b1 rdf:first sg:person.01044433531.92
175 rdf:rest N8815c846ad9047fda2fe87336f418e31
176 Nff6371ce430d4d0d81ab452d1bec4061 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Proto-Oncogene Proteins B-raf
178 rdf:type schema:DefinedTerm
179 Nfffedaaac7fe48c692135d0b0f48b43e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Colorectal Neoplasms
181 rdf:type schema:DefinedTerm
182 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
183 schema:name Medical and Health Sciences
184 rdf:type schema:DefinedTerm
185 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
186 schema:name Oncology and Carcinogenesis
187 rdf:type schema:DefinedTerm
188 sg:grant.8569345 http://pending.schema.org/fundedItem sg:pub.10.1007/s00259-019-04555-6
189 rdf:type schema:MonetaryGrant
190 sg:journal.1297401 schema:issn 1619-7070
191 1619-7089
192 schema:name European Journal of Nuclear Medicine and Molecular Imaging
193 schema:publisher Springer Nature
194 rdf:type schema:Periodical
195 sg:person.01006327107.21 schema:affiliation grid-institutes:grid.16872.3a
196 schema:familyName Huisman
197 schema:givenName M. C.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006327107.21
199 rdf:type schema:Person
200 sg:person.010151641705.79 schema:affiliation grid-institutes:grid.10417.33
201 schema:familyName Boon
202 schema:givenName E.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010151641705.79
204 rdf:type schema:Person
205 sg:person.01044433531.92 schema:affiliation grid-institutes:grid.7692.a
206 schema:familyName Elias
207 schema:givenName S. G.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044433531.92
209 rdf:type schema:Person
210 sg:person.011543041217.55 schema:affiliation grid-institutes:grid.16872.3a
211 schema:familyName Verheul
212 schema:givenName H. M. W.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011543041217.55
214 rdf:type schema:Person
215 sg:person.011656526207.74 schema:affiliation grid-institutes:grid.16872.3a
216 schema:familyName van Grieken
217 schema:givenName N. C. T.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011656526207.74
219 rdf:type schema:Person
220 sg:person.01204115344.29 schema:affiliation grid-institutes:grid.4830.f
221 schema:familyName van Es
222 schema:givenName S. C.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204115344.29
224 rdf:type schema:Person
225 sg:person.01250717536.24 schema:affiliation grid-institutes:grid.16872.3a
226 schema:familyName Dekker
227 schema:givenName H.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01250717536.24
229 rdf:type schema:Person
230 sg:person.012766300443.59 schema:affiliation grid-institutes:grid.4830.f
231 schema:familyName de Vries
232 schema:givenName E. G. E.
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012766300443.59
234 rdf:type schema:Person
235 sg:person.01361420011.63 schema:affiliation grid-institutes:grid.16872.3a
236 schema:familyName Boellaard
237 schema:givenName R.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361420011.63
239 rdf:type schema:Person
240 sg:person.014562003237.68 schema:affiliation grid-institutes:grid.10417.33
241 schema:familyName van Herpen
242 schema:givenName C. M. L.
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014562003237.68
244 rdf:type schema:Person
245 sg:person.0621551653.25 schema:affiliation grid-institutes:grid.16872.3a
246 schema:familyName Hoekstra
247 schema:givenName O. S.
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0621551653.25
249 rdf:type schema:Person
250 sg:person.0624671657.22 schema:affiliation grid-institutes:grid.16872.3a
251 schema:familyName van Helden
252 schema:givenName E. J.
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624671657.22
254 rdf:type schema:Person
255 sg:person.0644704274.30 schema:affiliation grid-institutes:grid.424926.f
256 schema:familyName Oyen
257 schema:givenName W. J. G.
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644704274.30
259 rdf:type schema:Person
260 sg:person.0665425270.49 schema:affiliation grid-institutes:grid.16872.3a
261 schema:familyName Vugts
262 schema:givenName D. J.
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665425270.49
264 rdf:type schema:Person
265 sg:person.0704276650.01 schema:affiliation grid-institutes:grid.16872.3a
266 schema:familyName Menke-van der Houven van Oordt
267 schema:givenName C. W.
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704276650.01
269 rdf:type schema:Person
270 sg:person.0732223564.35 schema:affiliation grid-institutes:grid.16872.3a
271 schema:familyName van Dongen
272 schema:givenName G. A. M. S.
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732223564.35
274 rdf:type schema:Person
275 sg:person.0755073020.01 schema:affiliation grid-institutes:grid.4830.f
276 schema:familyName Brouwers
277 schema:givenName A. H.
278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755073020.01
279 rdf:type schema:Person
280 sg:person.0775731665.95 schema:affiliation grid-institutes:grid.16872.3a
281 schema:familyName Gerritse
282 schema:givenName S. L.
283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775731665.95
284 rdf:type schema:Person
285 sg:pub.10.1007/s00259-014-2961-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1008918527
286 https://doi.org/10.1007/s00259-014-2961-x
287 rdf:type schema:CreativeWork
288 sg:pub.10.1038/35025220 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043028620
289 https://doi.org/10.1038/35025220
290 rdf:type schema:CreativeWork
291 sg:pub.10.1038/bjc.2015.173 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048637377
292 https://doi.org/10.1038/bjc.2015.173
293 rdf:type schema:CreativeWork
294 sg:pub.10.1038/clpt.2010.12 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037850597
295 https://doi.org/10.1038/clpt.2010.12
296 rdf:type schema:CreativeWork
297 grid-institutes:grid.10417.33 schema:alternateName Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
298 schema:name Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
299 rdf:type schema:Organization
300 grid-institutes:grid.16872.3a schema:alternateName Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands
301 Pathology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands
302 Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands
303 schema:name Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands
304 Pathology, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands
305 Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Location VU Medical Center, Amsterdam, The Netherlands
306 rdf:type schema:Organization
307 grid-institutes:grid.424926.f schema:alternateName The Institute of Cancer Research and The Royal Marsden Hospital, London, UK
308 schema:name Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
309 The Institute of Cancer Research and The Royal Marsden Hospital, London, UK
310 rdf:type schema:Organization
311 grid-institutes:grid.4830.f schema:alternateName Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
312 Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
313 schema:name Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
314 Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
315 rdf:type schema:Organization
316 grid-institutes:grid.7692.a schema:alternateName Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
317 schema:name Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
318 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...